Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.40 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 3/20 | 0.38 |
| ▸ | GAK | O14976 | 2/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 2/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857240 | 0.92 | NCF1 (0.48) | NCF1KDREHMT2EHMT1ADRA1D | |
| SCHEMBL857227 | 0.88 | PDGFRB (0.41) | NCF1KDREHMT2EHMT1LCK | |
| SCHEMBL859609 | 0.85 | NCF1 (0.42) | NCF1KDREHMT2EHMT1LCK | |
| SCHEMBL856582 | 0.83 | NCF1 (0.42) | NCF1KDREHMT2EHMT1LCK | |
| SCHEMBL857346 | 0.82 | NCF1 (0.45) | NCF1KDREHMT2EHMT1ADRA1D | |
| SCHEMBL3763643 | 0.81 | NCF1 (0.47) | NCF1KDREHMT2EHMT1LCK | |
| SCHEMBL855221 | 0.81 | NCF1 (0.52) | NCF1KDREHMT2EHMT1LCK | |
| SCHEMBL13056703 | 0.77 | GPR142 (0.39) | NCF1KDREHMT2EHMT1LCK | |
| SCHEMBL3715695 | 0.77 | KDR (0.39) | NCF1KDREHMT2EHMT1LCK | |
| SCHEMBL856776 | 0.77 | CREBBP (0.48) | NCF1GPR142 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | NCF1 3080/4885KDR 2561/4885EHMT2 3871/4885 |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | NCF1 2814/4885KDR 2886/4885EHMT2 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.